MedTrace Logo

A Phase I Clinical Study of a Single Dose of KLA480

NCT07030790 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-06-22

No results posted yet for this study

Summary

Primary purpose:

To evaluate the safety and tolerability of KLA480 injection after a single subcutaneous injection in healthy participants.

Secondary purpose:

To evaluate the pharmacokinetic (PK) characteristics of KLA480 injection after a single subcutaneous injection in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

KLA480 injection

Subcutaneous injection，Single dose

DRUG

Placebo

Subcutaneous injection，Single dose

Sponsors & Collaborators

  • Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-17
Primary Completion
2026-12-31
Completion
2027-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07030790 on ClinicalTrials.gov